These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17325841)

  • 1. Managing plasma cell leukemia.
    Gertz MA
    Leuk Lymphoma; 2007 Jan; 48(1):5-6. PubMed ID: 17325841
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide administration for the treatment of resistant plasma cell leukemia.
    Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL
    Acta Haematol; 2003; 109(3):153-5. PubMed ID: 12747371
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.
    Petrucci MT; Martini V; Levi A; Gallucci C; Palumbo G; Del Bianco P; Torromeo C; Foà R
    Leuk Lymphoma; 2007 Jan; 48(1):180-2. PubMed ID: 17325863
    [No Abstract]   [Full Text] [Related]  

  • 4. [Plasma cell leukaemia].
    Rodriguez C; Pont JC; Gouin-Thibault I; Andrieu AG; Molina T; Le Tourneau A; Le Garff-Tavernier M; Siguret V; Chaibi P
    Ann Biol Clin (Paris); 2005; 63(5):535-9. PubMed ID: 16230292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report.
    Olivieri A; Attolico I; Cimminiello M; Discepoli G; Cifarelli RA
    Leuk Res; 2009 Nov; 33(11):e191-3. PubMed ID: 19476997
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.
    Wöhrer S; Ackermann J; Baldia C; Seidl S; Raderer M; Simonitsch I; Drach J
    Hematol J; 2004; 5(4):361-3. PubMed ID: 15297854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.
    Benson DM; Smith MK
    Leuk Lymphoma; 2007 Jul; 48(7):1423-5. PubMed ID: 17613775
    [No Abstract]   [Full Text] [Related]  

  • 8. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
    Pretz J; Medeiros BC
    Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102
    [No Abstract]   [Full Text] [Related]  

  • 9. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.
    Ballanti S; Mastrodicasa E; Bolli N; Lotti F; Capolsini I; Berchicci L; Merigiola C; Giordano G; Tabilio A
    Nat Clin Pract Oncol; 2007 Dec; 4(12):722-5. PubMed ID: 18037876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
    Musto P; Pietrantuono G; Guariglia R; Villani O; Martorelli MC; D'Auria F; Zonno A; Lerose R
    Leuk Res; 2008 Oct; 32(10):1637-8. PubMed ID: 18433866
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.
    Mele G; Coppi MR; Guaragna G; Spina A; Melpignano A
    Leuk Res; 2016 Jan; 40():30-2. PubMed ID: 26626205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment.
    Brück P; Mousset S; Bühme A; Hoelzer D; Atta J
    Int J Hematol; 2007 Jul; 86(1):66-8. PubMed ID: 17675269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2015 Jan; 56(1):232-5. PubMed ID: 24884320
    [No Abstract]   [Full Text] [Related]  

  • 14. [Plasma cell leukemia resistant to chemotherapy, with special reference to cytogenetic markers, 14q+ and double minute chromosomes].
    Yamane Y; Edagawa J; Nishida K; Tsuda S; Maekawa T; Taniwaki M; Sonoda Y; Misawa S; Abe T; Takino T
    Rinsho Ketsueki; 1984 Mar; 25(3):365-71. PubMed ID: 6590889
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
    Simeon V; Todoerti K; La Rocca F; Caivano A; Trino S; Lionetti M; Agnelli L; De Luca L; Laurenzana I; Neri A; Musto P
    Int J Mol Sci; 2015 Jul; 16(8):17514-34. PubMed ID: 26263974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
    Mian M; Tinelli M; DE March E; Turri G; Meneghini V; Pescosta N; Berno T; Marabese A; Mondello P; Patriarca F; Pizzolo G; Semenzato G; Cortelazzo S; Zambello R
    Anticancer Res; 2016 Mar; 36(3):1059-65. PubMed ID: 26976998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide in the treatment of plasma cell malignancies.
    Rajkumar SV; Kyle RA
    J Clin Oncol; 2001 Aug; 19(16):3593-5. PubMed ID: 11504740
    [No Abstract]   [Full Text] [Related]  

  • 18. [Thalidomide: new therapeutic indications?].
    Nau JY
    Rev Med Suisse; 2010 Apr; 6(245):846-7. PubMed ID: 20469670
    [No Abstract]   [Full Text] [Related]  

  • 19. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
    Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
    Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
    Krüger WH; Kiefer T; Schüler F; Lotze C; Busemann C; Dölken G
    Onkologie; 2007 Apr; 30(4):193-5. PubMed ID: 17396042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.